Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurocrine Biosciences Inc.

www.neurocrine.com

Latest From Neurocrine Biosciences Inc.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

US FDA Performance Tracker Drug Approval Standards

Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend

Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.

Financing Business Strategies

Teva’s Austedo Fails In Tourette’s Syndrome

Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.

Clinical Trials Companies

Teva Edges Closer To Growth, But With A Big Overhang

Teva's turnaround is progressing, but the company forecast largely flat revenues and earnings in 2020. A threat to the improved stability is how an opioid litigation settlement might unfold.

Sales & Earnings Generic Drugs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Neurocrine Biosciences Inc.
  • Senior Management
  • Kevin C Gorman, PhD, CEO
    Kyle Gano, PhD, Chief Bus. Dev. Officer
    Haig Bozigian, PhD, Chief Dev. Officer
    Dimitri Grigoriadis, PhD, Chief Research Officer
    Malcolm Lloyd-Smith , Chief Reg. Officer
    Christopher O'Brien, MD, CMO
  • Contact Info
  • Neurocrine Biosciences Inc.
    Phone: (858) 617-7600
    12780 El Camino Real
    San Diego, CA 92130
    USA
UsernamePublicRestriction

Register